Journals in Pharmacology
Journals in Pharmacology
Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.
- ISSN: 1559-7814
PET Clinics: Continuing Medical Education Program
Earn CME the Clinics way and save!Earn CME credit while reading your Clinics issues! Subscribers to Clinics CME can earn up to 60 AMA PRA Category 1 Credit(s)™ each year by completing one of our customized CME programs, accredited by the Elsevier Office of Continuing Medical Education.How it works: Exam booklets are available online to Clinics CME Program subscribers about a month after each Clinics issue (available as a separate subscription) publishes. Read the issue and take the exam for instant AMA PRA Category 1 Credit(s)™ online! Certificates can be printed immediately upon completion of the exam and program evaluation. A personal user account (MyCME) records all exam results and credits, and allows users to save in-progress exams and complete them at a later date.This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the Elsevier Office of Continuing Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.More information: http://www.pet.thecl...
- ISSN: 0014-2999
European Journal of Pharmacology
The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.The scope includes: Behavioural pharmacology, Neuropharmacology and psychopharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Endocrine pharmacology, Immunopharmacology and inflammation, Molecular and cellular pharmacology, Regenerative pharmacology, Biologicals and biotherapeutics, Translational pharmacology and Nutriceutical pharmacology.The journal publishes full-length papers and reviews. Ethnopharmacological studies with plant extracts or mixtures are not in scope of this journal.The table of contents for this journal is now available pre-publication, via e-mail, as part of the free ContentsDirect service from Elsevier. Please send an e-mail message to [email protected]... for further information about this service.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
- ISSN: 0367-326X
Fitoterapia
The Journal for the Study of Medicinal PlantsA Q1-ranked journal in the category of 'Agricultural and Biological Sciences' (Scopus).Fitoterapia is a Journal dedicated to medicinal plants and fungi and to the bioactive natural products produced by these organisms. It publishes original contributions in seven major areas:1. Chemical characterization of active ingredients of medicinal plants and fungi, including their endophytes 2. New analytical approaches for dereplication and standardization of biologically active extracts and metabolites from plant resources 3. Identification of bioactivity in plant and fungal extracts and in their constituents 4. Identification of biological targets and mechanism of activity of plant and fungal extracts 5. Production and genomic characterization of medicinal plants biomass 6. Biosynthesis of bioactive natural products of plant, fungi and endophytic origin 7. Critical reviews of the composition, history, clinical and legal status of medicinal plants, and accounts on topical issues.Contributions reporting the following are NOT normally considered for publication: 1. Activity data on crude extracts that have not been characterized by analysis of their major constituents (HPLC fingerprint, LC/MS or NMR). Data on the extract composition simply taken from the literature are not acceptable. Characterization of only a few constituents is generally considered too partial. 2. Studies on the bioactivity of pure compounds purchased or obtained by Authors without any study or relationship with the producing organism. 3. Unexceptional and predictable bioactivity (e.g. antioxidant properties of phenolics or antibacterial activity of essential oils). 4. Uncritical ethnopharmacological investigations, where a list of plants and their use are simply recorded. 5. Genomic, transcriptomic and pharmacological studies without convincing wet lab experiments, or with little correlation to bioactive natural compounds.In addition, the following immediate rejection criteria apply: RULE 1: The manuscript does not fall into any of the areas of interest of the Journal. RULE 2: The manuscript is too preliminary, reporting e.g. activity data without comparison to a reference, or without a positive control. RULE 3: The botanical source is not clearly identified, authenticated, and documented (voucher). RULE 4: Characterization of new compounds without spectral supporting material. RULE 5: Bioactivity is not relevant to in vivo situations. RULE 6: Reviews on topics already covered in the recent literature.
- ISSN: 0006-2952
Biochemical Pharmacology
Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/tran... or drug/compound-induce... modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.Original research submissions must contain:A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulato... of receptors, enzymes and signaling pathways.Justificati... must also be provided for the selection of the statistical tests employed as they relate to the experimental design.It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.US National Institutes of Health (NIH) voluntary posting ("Public Access") policy:Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy.
- ISSN: 1551-7144
Contemporary Clinical Trials
Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers not exceeding 4,000 words, short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/comment... on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.The following topics are covered in the journal:Unconvention... design features of specific trials and their rationalePreliminary or full results of clinical trials with unconventional design featuresStatistical methods for all aspects of clinical trialsMethodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessmentData management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registriesRegulatory requirements and their impact on clinical trialsEthical and legal considerations in clinical trialsRisk-benefit, cost-effectiveness and decision analyses in clinical trialsContemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment.Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients.We look forward to receiving your contribution! Authors are also welcome to submit to the journal's open access companion title, Contemporary Clinical Trials Communications .Benefits to authors Contemporary Clinical Trials also provides many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
- ISSN: 1537-1891
Vascular Pharmacology
Vascular Pharmacology is a journal of Vascular Biology and Medicine. We seek to rapidly publish transformative papers, reviews, and perspectives on vascular cells across the disciplines of biochemistry, pharmacology, pathology, physiology, molecular and developmental biology, and clinical medicine using sophisticated tools in genomics/proteomics/... genetics, genome editing, and bioengineering.The journal will consider submissions that address vascular cells in the context of:Atherosclerosis, thrombosis, hemostasisNeurovascu... diseasesDiabetes, obesity, and metabolic syndromePulmonary hypertensionCardiova... toxicity induced by anticancer drugsTransplant arteriopathyVascular aging, repair, and regenerationReperfus... injuryImmunological influence in vascular diseasesMicrovascula... dysfunctionPlease check the latest journal related topics and articles on our Twitter account @VasPharma.
- ISSN: 0939-6411
European Journal of Pharmaceutics and Biopharmaceutics
Official Journal of the International Association for Pharmaceutical TechnologyThe European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.Top... covered include for example:Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)Aspects of manufacturing process designBiomedical aspects of drug product designStrategies and formulations for controlled drug transport across biological barriersPhysicochemi... aspects of drug product developmentNovel excipients for drug product designDrug delivery and controlled release systems for systemic and local applicationsNanomate... for therapeutic and diagnostic purposesAdvanced therapy medicinal productsMedical devices supporting a distinct pharmacological effect"The Rules of 3"The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work: 1. The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance. 2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented. 3. The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.
- ISSN: 1094-5539
Pulmonary Pharmacology & Therapeutics
Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immedia... rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).
- ISSN: 1471-4892
Current Opinion in Pharmacology
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis of current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight into areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR publishes the latest advancements in pharmacological sciences, covering, but not limited to, the following human systems:Cardiovascul... systemsDigestive and excretory systemsEndocrine systemImmune and lymphatic systemsMusculoskelet... systemNervous systemReproductive systemRespiratory systemUrinary and renal systemsAdditionally, COPHAR particularly welcomes submissions related to:CancerImmunomodul... disordersNeurologica... and psychiatric disordersEmerging technologiesGender and agingThe journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.Comprehensi... - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.Discovera... Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast, global audience.Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.Submissions... Opinion in Pharmacology allows two ways to submit to the journal:Invitation – in accordance with the established procedure for all Current Opinion titles, andNEW– authors are given a “spontaneous submission option” via the submission portal “General Pharmacology” at https://www.editoria... to open the journal to the authorship fully.Short Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it is useful to outline our expectations of authors and the procedures that the journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential; full disclosure to the journal is the safest course. All submissions to the journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier...
- ISSN: 0024-3205
Life Sciences
Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed.The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.Manuscripts should present novel preclinical findings addressing questions of biological significance to human disease. Studies that fail to do so may be rejected without review. Quantitative conclusions must be based on truly quantitative methods. Life Sciences does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration. The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment. Clinical studies may be considered if they expand understanding of mechanism, but the journal does not encourage clinical trial reports.Four common reasons for rejection include: out of scope (the manuscript does not conform to the goal of identification of mechanisms related to therapy for human disease); too preliminary (manuscript is based on a limited amount of experimental data diminishing significance); lack of novelty (manuscript is well done but does not address a significant question); unidentified structure (actions of biological extracts of unknown chemical composition).